Fig. 1.
Effect of pioglitazone (Pio) therapy (n=10), and of combined exenatide and pioglitazone (Ex+pio) therapy (n=11) on hepatic fat content (a, b) and fasting plasma FGF21 levels (c, d) in patients with type 2 diabetes. *p<0.05, **p<0.01 and ***p<0.001 for pre-therapy vs post-therapy; †p<0.05 for Ex+pio vs Pio